---
title: "Genius Sports Limited (GENI) Receives a Buy from Freedom Capital Markets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293257211.md"
description: "Genius Sports Limited received a Buy rating and price target from Freedom Capital Markets analyst today.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Genius Sports Limited has an analyst consensus of Strong Buy, with a price target consensus of $9.00."
datetime: "2026-07-20T21:25:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293257211.md)
  - [en](https://longbridge.com/en/news/293257211.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293257211.md)
generator: "portal-rs"
---

# Genius Sports Limited (GENI) Receives a Buy from Freedom Capital Markets

Genius Sports Limited received a Buy rating and price target from Freedom Capital Markets analyst today.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Genius Sports Limited has an analyst consensus of Strong Buy, with a price target consensus of $9.00.

### Related Stocks

- [GENI.US](https://longbridge.com/en/quote/GENI.US.md)

## Related News & Research

- [Genius Sports Announces Close of Acquisition of Legend | GENI Stock News](https://longbridge.com/en/news/284882468.md)
- [Goldman Sachs Keeps Their Hold Rating on Weibo (WB)](https://longbridge.com/en/news/296494184.md)
- [CrowdStrike (CRWD) Stock Could Swing 9% on Q2 Earnings, Options Market Signals](https://longbridge.com/en/news/296689129.md)
- [Lowe’s Earns Buy Rating as Strong Earnings and Cash Generation Offset Lower-End Guidance](https://longbridge.com/en/news/296383656.md)
- [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**